姚海荣, 田菁, 李迎春, 张文琪, 郝权. 卵巢癌腹水CD4+ CD25+调节性T细胞免疫抑制功能及机制的研究[J]. 中国肿瘤临床, 2014, 41(9): 560-565. DOI: 10.3969/j.issn.1000-8179.20132020
引用本文: 姚海荣, 田菁, 李迎春, 张文琪, 郝权. 卵巢癌腹水CD4+ CD25+调节性T细胞免疫抑制功能及机制的研究[J]. 中国肿瘤临床, 2014, 41(9): 560-565. DOI: 10.3969/j.issn.1000-8179.20132020
shu
YAO Hairong, TIAN Jing, LI Yingchun, ZhANG Wenqi, HAO Quan. Immuno-suppression and mechanism of CD4+ CD25+ T cells in ascites of ovarian cancer patients[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(9): 560-565. DOI: 10.3969/j.issn.1000-8179.20132020
Citation: YAO Hairong, TIAN Jing, LI Yingchun, ZhANG Wenqi, HAO Quan. Immuno-suppression and mechanism of CD4+ CD25+ T cells in ascites of ovarian cancer patients[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(9): 560-565. DOI: 10.3969/j.issn.1000-8179.20132020
shu

卵巢癌腹水CD4+ CD25+调节性T细胞免疫抑制功能及机制的研究

Immuno-suppression and mechanism of CD4+ CD25+ T cells in ascites of ovarian cancer patients

    摘要
  • 摘要:
      目的  研究卵巢癌患者腹水内CD4+ CD25+调节性T细胞（Treg）免疫抑制功能与患者临床病理特点的关系及其与患者初治及复发状态是否相关，并进一步探讨卵巢癌腹水内CD4+ CD25+调节性T细胞（Treg）发挥免疫调节性作用的具体机制。
      方法  应用免疫磁珠分选法分选28例卵巢癌患者腹水内CD4+ CD25+调节性T细胞及CD4+ CD25- T细胞，采用羧基荧光素二醋酸盐琥珀酰亚胺酯（carboxyfluorescein succinimidylester，CFSE）标记CD4+ CD25- T细胞，CD4+ CD25+ Treg与自体CFSE标记CD4+ CD25- T细胞以1:1比例共培养，经流式检测CFSE表达及Modfit软件分析CD4+ CD25- T增殖指数（PI），计算各标本内Treg对自体CD4+ CD25- T细胞增殖抑制率。应用中合性抗IL-10抗体及中合性抗TGF-β1抗体探究腹水内CD4+ CD25+ Treg介导免疫逃逸作用是否通过抑制性细胞因子IL-10或TGF-β1发挥作用。
      结果  Ⅲ~Ⅳ期卵巢癌腹水内CD4+ CD25+ Treg对自体CD4+ CD25- T细胞增殖抑制率为（75.72±17.04）%，较Ⅰ~Ⅱ期Treg抑制率（59.61±16.97）%显著增强（P < 0.05）。复发卵巢癌患者腹水内Treg对自体CD4+ CD25- T细胞增殖抑制率为（85.89±7.07）%，较初治卵巢癌患者腹水Treg抑制率（52.82±8.18）%显著增强（P=0.000 1）。共培养体系内加入中合性抗IL-10抗体或/及中和性抗TGF-β1抗体，Treg对自体CD4+ CD25- T细胞增殖抑制率较对照组均显著降低（P < 0.05）。
      结论  卵巢癌腹水内CD4+ CD25+ Treg介导免疫逃逸能力与肿瘤分期及复发、初治状态相关，且发挥免疫逃逸作用可能是与分泌抑制性细胞因子IL-10及TGF-β1有关。

     

    Abstract:
      Objective  This research explores the relationship between the immuno-suppression function of regulatory T cells (Treg) in the ascites of ovarian cancer (OC) patients, the clinico-pathologic features of these patients, and the correlation of the function of Treg with initial treatment and relapse status of the patients to further investigate the specific mechanism of immuno-regulatory function of CD4+ CD25+ Treg in the ascites of OC.
      Methods  Immuno-magnetic activated cell sorting (MACS) was conducted to sort CD4+ CD25+ Treg and autologous CD4+ CD25- Treg from the ascites of 28 OC patients. Carboxyfluorescein-diacetate succinimidyl ester (CFSE) was used to label the autologous CD4+ CD25- Treg. These labeled cells were then used as controls and co-cultured with autologous CD4+ CD25+ Treg at the ratio of 1:1 or 1:2. The mean inhibition ratio of Treg in specimens to the proliferation of autologous CD4+ CD25- Treg was calculated after the flow cytometry of the CFSE expression and Modfit software analysis of the CD4+ CD25- Treg proliferation index (PI) were performed. Anti-IL-10 and/or anti-TGF-β1 antibodies were neutralized to investigate whether the CD4+ CD25+ Treg-mediated immuno-suppression escaped through the ascites can produce a marked effect by the inhibitory cytokine IL-10 or TGF-β 1.
      Results  The mean inhibition ratio of CD4 + CD25- Treg in the ascites of stage Ⅲ to Ⅳ OC patients was (75.72±17.04)%, which is significantly higher than that of stageⅠtoⅡ OC patients (59.61±16.97)%; P < 0.05. In addition, Treg in the ascites of OC patients with recurrent disease showed a significantly higher inhibition ratio than that of patients with primary disease; P < 0.001. Moreover, Treg in groups added into neutralizing anti-IL-10 and/or anti-TGF-β1 antibodies displayed significantly lower depressant effect than the control group; P < 0.05.
      Conclusion  The immuno-suppression of CD4+ CD25+ Treg in the ascites of OC patients is correlated with the tumor staging and status of the primary or recurrent diseases. Moreover, Treg may indicate a suppressor function by secreting cytokine IL-10 and TGF-β1.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回